The government “There is no change in the introduction schedule so far…in consultation with individual suppliers”
“There is no alternative vaccine… need to analyze a rare thrombosis’viral vector’ vaccine”
As the new coronavirus infectious disease (Corona 19) vaccine, which the Korean government has decided to import, has been suspended or pushed to the top of the rank due to various unexpected variables, there is a growing possibility that the domestic introduction schedule will also be disrupted.
While U.S. health officials have recommended that Johnson & Johnson (J&J) stop vaccinating Janssen vaccine due to the occurrence of “rare thrombosis” after vaccination, Moderna has not clearly disclosed the vaccine supply schedule outside the U.S., which intensifies supply and demand. I’m doing it.
Experts raised the need for thorough safety testing as a vaccine that has not yet been introduced in Korea, such as Janssen, raised the need for a thorough safety test, but expressed regret that there was no other option to replace it.
◇ Possible delay in supply of domino food from Janssen vaccine
According to health officials on the 15th, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) reported that six Janssen vaccinations had a “rare and severe” form of thrombosis on the 13th (local time). It was recommended to stop vaccinating Janssen’s vaccine.
CDC convened an emergency meeting of the Vaccination Advisory Committee (ACIP), a vaccine advisory body, to review the safety of Janssen’s vaccine.However, if the approval for emergency use is withdrawn or restricted to specific population groups, domestic vaccination plans will also have an impact. I have no choice but to receive.
The schedule for supplying modders and vaccines is also uncertain.
US pharmaceutical company Moderna announced on its website the day before, “We plan to supply 100 million doses (for 50 million people) of vaccine to the US government by the end of May and an additional 100 million doses by the end of July.” As for the supply chain, it is (scheduled) to be supplied about a quarter later than the US supply chain, but the amount of vaccines is currently being increased,” he said.
If demand for modders or vaccines in the U.S. surges in the aftermath of the suspension of Janssen vaccination, there may be a delay in supply of dominoes in the order of country-specific contracts.
Of course, the Korean government has yet to change the vaccine schedule.
Baek Young-ha, head of the vaccine introduction team at the Central Accident Control Headquarters, said at a briefing the day before that “the domestic introduction plan has not yet changed regarding the suspension of the Janssen vaccine in the US.”
Also, regarding the vaccines scheduled to be introduced in the second quarter, including Janssen, he said, “there is currently a discussion with each vaccine supplier,” and “the plan has not been confirmed in detail, and we will disclose it as soon as it is confirmed.”
The total number of vaccines the government has secured so far is 79 million people.
The amount of supply confirmed in the first half of the year is 9044,000 people (18,088,000 doses), and negotiations are underway with the goal of introducing an additional 2712,000 doses of Janssen, Modena, and NovaVax vaccines in the second quarter.
◇ “The Janssen vaccination stopped, a major blow to the country…Thrombosis detection and treatment methods should be considered
Experts were concerned that the aftermath of the Janssen vaccination cessation would have a major impact on Korea, and stressed that we need to find the best response to our situation.
Jeong Jae-hoon, a professor of preventive medicine at Gachon University Medical School, said, “The US’ recommendation to stop vaccinating Janssen will of course have an impact on the domestic market as well.”
Professor Jeong said that as Janssen vaccination has not yet begun in Korea, it is necessary to quickly collect relevant information from overseas cases and monitor the situation.
“Alternative vaccines cannot be a complete alternative in situations where there is absolutely no vaccine supply,” he added. “Realistically, we need to find a way to use our vaccines most effectively and safely.”
Professor Jeong added that one of them should be to limit the vaccination age, like the AstraZeneca (AZ) vaccine, or how to find and treat rare thrombosis after vaccination.
Kim Nam-jung, a professor of infectious medicine at Seoul National University Hospital, said, “I tried to bring 6 million doses of Janssen vaccine to Korea, but it could not be used right away,” he said. “As there are many variables, it will hurt us as well.”
Professor Kim said, “Because there is no Janssen vaccine in our country yet, we need to keep an eye on the situation,” he said. “It would be nice if there was an alternative vaccine, but it wasn’t right.”
Experts also said that the rare thrombosis problem common to both the AstraZeneca and Janssen vaccines may be a platform problem rather than a vaccine itself, and the research results should be carefully reviewed.
Professor Jeong said that both AstraZeneca vaccine and Janssen vaccine are vaccines that utilize a’viral vector’ (carrier) platform, and estimated that “it may be a problem of the’platform’, not of the vaccine itself.”
“There may be a possibility that the carrier itself can cause rare thrombosis, but the Janssen vaccination results seem to be realizing that concern.”
Professor Chun Byeong-cheol of the Department of Preventive Medicine at Korea University also said, “Whether the Janssen vaccine or the AstraZeneca vaccine, we need to evaluate the results of thrombosis-related studies that have been released.” Insisted.
Professor Chun also added, “Since both vaccines have not been made, there is no accumulated data.”
/yunhap news